Cargando…
Clinical development of metabolic inhibitors for oncology
Metabolic inhibitors have been used in oncology for decades, dating back to antimetabolites developed in the 1940s. In the past 25 years, there has been increased recognition of metabolic derangements in tumor cells leading to a resurgence of interest in targeting metabolism. More recently there has...
Autores principales: | Lemberg, Kathryn M., Gori, Sadakatali S., Tsukamoto, Takashi, Rais, Rana, Slusher, Barbara S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718137/ https://www.ncbi.nlm.nih.gov/pubmed/34981784 http://dx.doi.org/10.1172/JCI148550 |
Ejemplares similares
-
D-DOPA Is a Potent, Orally Bioavailable, Allosteric Inhibitor of Glutamate Carboxypeptidase II
por: Gori, Sadakatali S., et al.
Publicado: (2022) -
Glutamine Antagonist GA-607 Causes a Dramatic Accumulation of FGAR which can be used to Monitor Target Engagement
por: Alt, Jesse, et al.
Publicado: (2021) -
Discovery of tert-Butyl Ester Based
6-Diazo-5-oxo-l-norleucine Prodrugs
for Enhanced Metabolic Stability and Tumor Delivery
por: Novotná, Kateřina, et al.
Publicado: (2023) -
Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug
por: Rais, Rana, et al.
Publicado: (2022) -
6-Hydroxy-1,2,4-triazine-3,5(2H,4H)-dione Derivatives as Novel d-Amino Acid Oxidase Inhibitors
por: Hin, Niyada, et al.
Publicado: (2015)